Luca M Zaeck, Ngoc H Tan, Wim J R Rietdijk, Daryl Geers, Roos S G Sablerolles, Susanne Bogers, Laura L A van Dijk, Lennert Gommers, Leanne P M van Leeuwen, Sharona Rugebregt, Abraham Goorhuis, Douwe F Postma, Leo G Visser, Virgil A S H Dalm, Melvin Lafeber, Neeltje A Kootstra, Anke L W Huckriede, Bart L Haagmans, Debbie van Baarle, Marion P G Koopmans, P Hugo M van der Kuy, Corine H GeurtsvanKessel, Rory D de Vries
Waning antibody responses after COVID-19 vaccination combined with the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination with that of Omicron BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, or EG.5.1. Here, we report post-hoc analyses of data from the SWITCH-ON study, assessing how different COVID-19 priming regimens affect the immunogenicity of bivalent booster vaccinations and breakthrough infections (NCT05471440)...
May 18, 2024: Nature Communications